286 related articles for article (PubMed ID: 26528855)
1. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
Perez M; Muñoz-Galván S; Jiménez-García MP; Marín JJ; Carnero A
Oncotarget; 2015 Dec; 6(38):40557-74. PubMed ID: 26528855
[TBL] [Abstract][Full Text] [Related]
2. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
3. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
4. A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence.
Acevedo M; Vernier M; Mignacca L; Lessard F; Huot G; Moiseeva O; Bourdeau V; Ferbeyre G
Cancer Res; 2016 Jun; 76(11):3252-64. PubMed ID: 27206849
[TBL] [Abstract][Full Text] [Related]
5. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
6. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.
Francis AM; Alexander A; Liu Y; Vijayaraghavan S; Low KH; Yang D; Bui T; Somaiah N; Ravi V; Keyomarsi K; Hunt KK
Mol Cancer Ther; 2017 Sep; 16(9):1751-1764. PubMed ID: 28619757
[TBL] [Abstract][Full Text] [Related]
8. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
9. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
[TBL] [Abstract][Full Text] [Related]
11. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
12. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
13. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
14. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J; Martinez-Garcia J; Moura DS; Redondo A; Gutierrez A; Lopez-Pousa A; Martinez-Trufero J; Sevilla I; Diaz-Beveridge R; Solis-Hernandez MP; Carnero A; Perez M; Marcilla D; Garcia-Foncillas J; Romero P; Fernandez-Jara J; Lopez-Lopez D; Arribas I; Hindi N
Signal Transduct Target Ther; 2023 Oct; 8(1):405. PubMed ID: 37875500
[TBL] [Abstract][Full Text] [Related]
16. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: CDK4 inhibitors for cancer therapy.
Dickson MA
Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
19. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
20. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
